AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Sign up Log in

IMUGENE LIMITED Board/Management Information 2016

May 26, 2016

65124_rns_2016-05-26_d4f4a23e-6b7a-4b31-a815-1a3e02b37018.pdf

Board/Management Information

Open in viewer

Opens in your device viewer

==> picture [167 x 75] intentionally omitted <==

Imugene Corporate Development update

Melbourne, Australia, 27 May 2016: Imugene Limited (ASX: IMU), a clinical stage immunooncology company, announces that Stuart Roberts is transitioning to a consulting role within the company while pursuing other opportunities within the biotechnology industry. Mr Roberts, who is based in Sydney, will continue to manage investor relations for Imugene as well as shareholder communication.

About Imugene

Imugene (ASX: IMU) is a clinical stage immuno-oncology company headquartered in Melbourne, Australia. Its lead product is HER-Vaxx, a B Cell peptide vaccine for the treatment of gastric cancer. The company is also developing mimotope-based immunotherapies against validated and new oncology targets.

HER-Vaxx is a cancer immunotherapy designed to treat tumours that over-express the HER-2/neu receptor, such as gastric, breast, ovarian, lung and pancreatic cancers. This unique immunotherapy, developed by leading scientists at the Medical University of Vienna in Austria, is a peptide vaccine constructed from various B cell epitopes of HER-2/neu. It has been shown in pre-clinical work and in one Phase 1 study to stimulate a potent polyclonal antibody response to HER-2/neu, a well-known and validated cancer target. HER-Vaxx’s successful Phase 1 study was in patients with breast cancer and the next stage of development will be a Phase 1b/2 study in patients with gastric cancer initiating in 2016.

In January 2016, Imugene announced a new partnership with the Medical University of Vienna to discover and develop mimotope-based immunotherapies against validated and new oncology targets. This partnership has the potential to create game-changing B Cell peptide vaccines that would replace or augment conventional monoclonal antibodies.

For further information, please visit www.imugene.com. Sign up to follow @TeamImugene on Twitter at http://www.twitter.com/TeamImugene. To follow Imugene on Facebook visit www.facebook.com/imugene.

For further information please contact:

Imugene: